Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Wisconsin, Madison
With
Medical College of Wisconsin
Optimum Therapeutics, LLC
Ohio State University
The overall purpose of the study is to determine whether or not the inclusion of suramin to standard treatment with docetaxel improves progression-free survival for patients with advanced non-small cell lung cancer in the second and third line settings.
Secondary objectives include:
* To compare response rate of patients in both treatment arms
* To compare overall survival of patients in both treatment arms
* To compare toxicity in both treatment arms
* To determine whether the survival benefit from suramin is associated with reduced M-phase entry in peripheral blood lymphocytes
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pathologically proven diagnosis of non-small cell lung cancer
Documented disease progression after first-line chemotherapy for non-small cell lung cancer
Stable and treated CNS metastasis is allowed
Radiation must be completed at least 2 weeks prior to starting protocol treatment
Major surgery must be completed at least 4 weeks prior to starting protocol treatment
ECOG performance status 0-2
Sexually active patients must use adequate contraception
Adequate bone marrow function
Adequate renal function
Adequate liver function
You may not be if
Severe hypersensitivity reaction to docetaxel
Pre-existing grade 3 or 4 neuropathy
Women who are pregnant or breastfeeding
Uncontrolled intercurrent illness
Receipt of 3 or more prior chemotherapy regimens
Clareo Health | Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer
